Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis

Fri Jan 04 2019

New abstract published in BMC Nephrology;

“Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab” by Alachkar N. et al.


“In this study of post transplant FSGS patients managed with TPE and rituximab, the reduction of suPAR after treatment contributed significantly to the reduction in proteinuria as well as to the response to therapy. These findings support monitoring of suPAR in TPE and rituximab managed recurrent and de novo FSGS”.

pdfLink to abstract here


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates